Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings, Inc. (ASRT) reported a net product sales of $26.4 million for Q1 2021, a decrease from $28.3 million pro forma sales in Q1 2020. The company's net income fell to $4.5 million from $41.2 million year-over-year. However, Adjusted EBITDA surged to $15.7 million compared to $3.9 million in the previous year. Assertio anticipates full-year 2021 net sales between $85.0 million and $92.0 million. The company has raised $45.3 million in cash to enhance liquidity and implemented a restructuring plan aiming for $45 million in annualized cost savings.
Assertio Holdings and Cove have partnered to enhance patient access to CAMBIA (diclofenac potassium) and SPRIX (ketorolac tromethamine) through Cove’s telemedicine platform. This collaboration aims to facilitate consultations with licensed physicians who can prescribe these medications for migraine treatment and pain management. The initiative aligns with Assertio's strategy for digital engagement and direct-to-patient care models, potentially expanding their reach in the market and improving patient convenience.
Assertio Holdings, Inc. (NASDAQ: ASRT) will announce its first quarter 2021 financial results on May 6, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results. Investors can access the live webcast at Assertio's investor relations website. Assertio is recognized for its differentiated pharmaceutical products in neurology, hospital, and pain management, having experienced growth through licensing and acquisitions.
Assertio Holdings reported full-year 2020 net product sales of $93.5 million and pro forma revenue of $119.2 million, aligning with guidance. The company raised $45.3 million in cash through direct offerings, enhancing liquidity. Assertio achieved $40 million in annual cost savings and expects an additional $45 million post-restructuring. Significant debt repayment included $450.2 million in 2020. However, the company faces challenges due to COVID-19's impact on elective procedures and a decline in prescription volumes.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced that Dan Peisert, its President and CEO, will present at the 33rd Annual Roth Conference on March 15, 2021. The virtual presentation is scheduled for 5:00 pm ET and will be available via live audio webcast on the company's investor website. A replay will also be accessible post-event. Assertio specializes in bringing differentiated pharmaceutical products to market, focusing on neurology, hospital, and pain management.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced that it will release its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call with management is scheduled for 4:30 p.m. Eastern Time on the same day. Assertio is noted for its differentiated pharmaceutical products in neurology, hospital, and pain and inflammation segments. Investors can access the live webcast and replay via the company’s investor website.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced the closure of a registered direct offering, raising approximately $34.3 million at $0.98 per share.
After fees, the net proceeds are about $32.1 million, meant for general corporate purposes and working capital.
The offering was made under an effective shelf registration statement and involved Roth Capital Partners as the placement agent.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced a securities purchase agreement with institutional investors to sell 35 million shares at $0.98 per share, raising approximately $34.3 million before expenses. The registered direct offering is set to close on February 12, 2021. Funds will be used for general corporate purposes. The offering falls under a shelf registration statement declared effective by the SEC on February 4, 2021. Roth Capital Partners is the sole placement agent for this transaction.
Assertio Holdings, Inc. (NASDAQ: ASRT) has completed a registered direct offering of common stock priced at $0.62 per share, totaling approximately $14 million in gross proceeds. After fees and expenses, net proceeds are expected to be around $13 million, which will be used for general corporate purposes, including working capital. This offering was conducted under an effective shelf registration statement filed with the SEC.
Assertio Holdings, Inc. (NASDAQ: ASRT) has announced a registered direct offering of 22,600,000 shares at a price of $0.62 per share, expected to close on February 9, 2021. The offering aims to raise approximately $14 million before fees. Proceeds will be allocated for general corporate purposes and working capital. Roth Capital Partners acted as the sole placement agent. This is being offered under a shelf registration statement filed with the SEC, and details will be available in a prospectus supplement.